DSM is launching its new 3C process technology, which delivers highly-concentrated (up to 85%) and customizable combinations of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) for both pharmaceutical and dietary supplement applications, while providing peace of mind through a consistent supply chain.

DSM 3C Technology is an efficient process technology that makes high-concentrate omega-3 EPA + DHA more accessible and relevant to consumers, the company said. This technology will be a catalyst for category growth by helping to eliminate key barriers to consumption of omega-3 supplements such as capsule size. In addition, it provides brand owners with the versatility to innovate tailored health-focused products to meet consumer needs across a lifetime.

“A large and growing body of evidence shows that insufficient levels of omega-3 EPA + DHA may be associated with serious health complications for many Americans,” said Michael McBurney, PhD, FACN, VP of Science, Communications and Advocacy, DSM Nutritional Products. Low levels of omega-3 are related to increased risk of cardiovascular disease, which is the leading cause of death among both men and women in the United States. Currently, 95.7% of Americans are not consuming enough omega-3 EPA + DHA to reach cardioprotective levels.

DSM has kicked off the “Modern Movement Forward” marketing campaign to inspire category change through 3C technology. “This new technology truly makes the oversized pills of traditional fish oil with low EPA & DHA omega 3 content a thing of the past,” said Tobe Cohen, Vice President, DSM Nutritional Products. The campaign will be brought to life at the DSM Booth GG 143. Visitors will learn more about a new line of next generation omega-3, called MEG-3 Ultra produced with 3C Technology.